Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Sweden

European Innovation Council · Running

AHM Acorai Heart Monitor - Non-invasive multi-sensor device for heart failure monitoring

Coordinator
Iaroca AB, Sweden
Runs
1 October 2023 to 31 May 2025
Status
Running
EU funding
€2.3m
Total cost
€3.4m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
101145549

What the project is doing

In the project's own words, from its summary on CORDIS.

Heart Failure is a progressive clinical syndrome with multiple etiologies. It is associated with nearly three million hospitalizations in the EU annually, representing 30% of all readmissions, and accounts for up to 5% of the entire healthcare expenditure. Despite modern medical treatment, HF is a life-threatening and debilitating condition with a poor prognosis. The Acorai Heart Monitor (AHM) is a monitoring device designed to detect and estimate hemodynamic parameters non-invasively.

AHM is a handheld electronic device that features multiple sensors to collect data from 4 sensor types based upon patented the SAVE sensor system to estimate the absolute pressure of the heart failure patient's cardiac system. The sensor data are processed within the medical device with machine learning (ML) methods, the results are then displayed to be read by a qualified healthcare professional (HCP). Delivering Intracardiac pressure to HCPs to guide the treatment of patients with HF leads to improved quality of life.

It lowers the frequency of hospital admissions, yet all current tools require an invasive procedure. AHM is a multi-patient non-invasive device that would dramatically disrupt the paradigm of HF treatment and lead to significant cost saving in the EU whilst improving the overall prognosis of patients who suffers from HF. With the growing prevalence of HF globally the AHM is a tool with applicability in multiple workflows and represents a first-of-its-kind device to revolutionise HF management.

AHM has already been validated in 300 patients in a Swedish proof of concept study and now needs the support to bring this device to market and collect data via a large multi-national study to prove its effectiveness. The AHM is fully patent protected with three granted patent families and four patents pending covering the core components of the device and its clinical application. This is additionally protected by large proprietary datasets and a unique ML model.

Topics

Who is involved

OrganisationCityCountryRole
Iaroca ABDomstenSwedenCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI